Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.63 |
| ▸ | KDR | P35968 | 6/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.63 |
| ▸ | FLT3 | P36888 | 4/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | FLT4 | P35916 | 2/20 | 0.63 |
| ▸ | ABL1 | P00519 | 2/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395430 | 1.00 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL17480352 | 0.88 | RET (0.62) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6320741 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6329722 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6765420 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6328758 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6320744 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL6767365 | 0.87 | RET (0.63) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL5830130 | 0.86 | KDR (0.51) | RETKDRALKFLT3PDGFRB | |
| SCHEMBL5830124 | 0.86 | KDR (0.51) | RETKDRALKFLT3PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | RET 3414/4885KDR 4431/4885ALK 4754/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | RET 842/4885KDR 1114/4885ALK 876/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | RET 348/4885KDR 484/4885ALK 1316/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | RET 4076/4885KDR 4776/4885ALK 4825/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | RET 3696/4885KDR 4866/4885ALK 4873/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | RET 107/4885KDR 327/4885ALK 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.